Stability Indicating RP-HPLC Method Development and Validation for Simultaneous Quantification of 15 Organic Impurities of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide in Combined Dosage Form

  • Pritesh R. DesaiEmail author
  • Priti J. Mehta
  • Avani B. Chokshi


A novel, simple, robust and rapid reversed-phased high performance liquid chromatographic method has been developed for the separation and quantitative determination of the 15 organic impurities of olmesartan medoxomil, amlodipine and hydrochlorothiazide in combined dosage forms. Successful separation of five impurities of olmesartan medoxomil, six impurities of amlodipine and four impurities of hydrochlorothiazide, and degradation products formed under stress conditions, was achieved on Inertsil ODS-3 (100 × 4.6 mm, 3.0 μm) column, using gradient elution. The mobile phase A contains 0.0 2 M phosphate buffer (pH 3.3) and acetonitrile in a ratio of (95:05, v/v%) and mobile phase B contains 0.02 M phosphate buffer (pH 3.3), acetonitrile and methanol in a ratio of (20:60:20, v/v/v%). Flow rate monitored at 1.8 mL min−1, and UV detection carried out at 237 nm. During forced degradation studies, the effect of acid, base, oxidation, UV light and temperature was investigated, showing good resolution between the peaks corresponding to process and degradation-related impurities. The performance of the method was validated according to the present ICH guidelines for specificity, linearity, accuracy, precision, ruggedness and robustness. To the best of our knowledge, this is the first research paper which presents a simple and rapid HPLC method, which separates all impurities of olmesartan medoxomil, amlodipine and hydrochlorothiazide in combined dosage forms.

Graphical Abstract


High-performance liquid chromatography Impurity Method validation Olmesartan medoxomil Amlodipine besylate Hydrochlorothiazide 



The authors of the current work wish to acknowledge the management of Zydus Cadila Healthcare Limited for supporting this work, and are grateful to their colleagues from Analytical Research and Development Laboratories.


This study was not funded by any grants.

Compliance with Ethical Standards

Conflict of interest

The authors declare that there is no conflict regarding publication of this paper.

Ethical approval

This article does not contain any studies with human participants/animals performed by any authors.


  1. 1.
    O'Neil MJ (2006) The merck index: an encyclopedia of chemicals, drugs, and biologicals, vol 14, pp 83, 827, 1178Google Scholar
  2. 2.
    Brousil JA, Burke JM (2003) Olmesartan medoxomil: an angiotensin II-receptor blocker. Clin Ther 25(4):1041–1055CrossRefGoogle Scholar
  3. 3.
    Püchler K, Nussberger J, Laeis P, Witte PU, Brunner HR (1997) Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens 15(12):1809–1812CrossRefGoogle Scholar
  4. 4.
    Martindale KP (2005) The extra pharmacopoeia. The Complete Drug Reference 34(3):2005Google Scholar
  5. 5.
    Mason RP, Marche P, Hintze TH (2003) Novel vascular biology of third-generation l-type calcium channel antagonists: ancillary actions of amlodipine. Arter Thromb Vasc Biol 23(12):2155–2163CrossRefGoogle Scholar
  6. 6.
    Stepien O, Zhang Y, Zhu D, Marche P (2002) Dual mechanism of action of amlodipine in human vascular smooth muscle cells. J Hypertens 20(1):95–102CrossRefGoogle Scholar
  7. 7.
    Barrett WE, Rutledge RA, Sheppard H, Plummer AJ (1959) The pharmacology of hydrochlorothiazide (Esidrix™), a new, orally effective sulfonamide diuretic. Toxicol Appl Pharmacol 1(4):333–349CrossRefGoogle Scholar
  8. 8.
    Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D (1998) The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 13(7):1682–1685CrossRefGoogle Scholar
  9. 9.
    Solini A, García-Donaire JA, Ruilope LM (2012) Combination therapy in hypertension. Curr Cardiovasc Risk Rep 6(4):291–298CrossRefGoogle Scholar
  10. 10.
    Rockville MD (2017) United States pharmacopeia and national formulary (USP 41-NF 36). United States Pharmacopeial Convention. Accessed 18 Jan 2018
  11. 11.
    Celebier M, Altinoz S (2007) Determination of olmesartan medoxomil in tablets by UV–Vis spectrophotometry. Pharmazie 62(6):419–422Google Scholar
  12. 12.
    Sridhar K, Sastry CSP, Reddy MN, Sankar DG, Srinivas KR (1997) Spectrophotometric determination of amlodipine besylate in pure forms and tablets. Anal Lett 30(1):121–133CrossRefGoogle Scholar
  13. 13.
    Merey HA, Ramadan NK, Diab SS, Moustafa AA (2014) Spectrophotometric methods for simultaneous determination of ternary mixture of amlodipine besylate, olmesartan medoxomil and hydrochlorothiazide. Spectrochim Acta A 125:138–146CrossRefGoogle Scholar
  14. 14.
    Bhusari KP, Khedekar PB, Dhole S, Banode VS (2009) Derivative and Q-analysis spectrophotometric methods for estimation of hydrochlorothiazide and olmesartan medoxomil in tablets. Indian J Pharm Sci 71(5):505CrossRefGoogle Scholar
  15. 15.
    Sharma T, Si SC, Gowrishankar D (2010) Difference spectrophotometric method for the determination of Olmesartan medoxomil in tablets. J Pharm Res 3(7):1553–1555Google Scholar
  16. 16.
    Patel J, Kevin G, Patel A, Raval M, Sheth N (2011) Development of the UV spectrophotometric method of Olmesartan medoxomil in bulk drug and pharmaceutical formulation and stress degradation studies. Pharm Methods 2(1):36CrossRefGoogle Scholar
  17. 17.
    Mehulkumar P, Ramesh V, Kumar VV, Srinivas R, Diwan PV (2009) Simultaneous spectroscopic estimation of amlodipine besylate and Olmesartan medoximil in tablet dosage form. Asian J Res Chem 2(2):127–130Google Scholar
  18. 18.
    Farouk M, EL-Aziz OA, Hemdanb A, Shehata M (2011) Simple novel spectrophotometric and spectrofluorimetric methods for determination of some antihypertensive Drugs. J Am Sci 7:300–312Google Scholar
  19. 19.
    Darwish HW, Bakheit AH, Darwish IA (2012) New spectrofluorimetric methods for the simultaneous determination of olmesartan medoxamil and amlodipine besylate in their combined tablets. Dig J Nanomater Bios 7:1599–1608Google Scholar
  20. 20.
    Bahrami GH, Mirzaeei SH (2004) Simple and rapid HPLC method for determination of amlodipine in human serum with fluorescence detection and its use in pharmacokinetic studies. J Pharm Biomed Anal 36(1):163–168CrossRefGoogle Scholar
  21. 21.
    Tatar S, Atmaca S (2001) Determination of amlodipine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 758(2):305–310CrossRefGoogle Scholar
  22. 22.
    Shah NJ, Suhagia BN, Shah RR, Patel NM (2007) Development and validation of a simultaneous HPTLC method for the estimation of olmesartan medoxomil and hydrochlorothiazide in tablet dosage form. Indian J Pharm Sci 69(6):834CrossRefGoogle Scholar
  23. 23.
    Solanki TB, Shah PA, Patel KG (2014) Central composite design for validation of HPTLC method for simultaneous estimation of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide in tablets. Indian J Pharm Sci 76(3):179Google Scholar
  24. 24.
    Kamble AY, Mahadik MV, Khatal LD, Dhaneshwar SR (2010) Validated HPLC and HPTLC method for simultaneous quantitation of amlodipine besylate and olmesartan medoxomil in bulk drug and formulation. Anal Lett 43(2):251–258CrossRefGoogle Scholar
  25. 25.
    Qi W, Zhao Q, Jiang J, Hu P (2013) Simultaneous determination of olmesartan and amlodipine in human plasma and urine by ultra performance liquid chromatography tandem mass spectrometry. J Chromatogr B 938:27–34CrossRefGoogle Scholar
  26. 26.
    Tiwari RN, Shah N, Bhalani V, Mahajan A (2015) LC, MSn and LC–MS/MS studies for the characterization of degradation products of amlodipine. J Pharmaceut Anal 5(1):33–42Google Scholar
  27. 27.
    Murakami T, Konno H, Fukutsu N, Onodera M, Kawasaki T, Kusu F (2008) Identification of a degradation product in stressed tablets of Olmesartan medoxomil by the complementary use of HPLC hyphenated techniques. J Pharm Biomed Anal 47(3):553–559CrossRefGoogle Scholar
  28. 28.
    Liu D, Jiang J, Wang P, Feng S, Hu P (2010) Simultaneous quantitative determination of olmesartan and hydrochlorothiazide in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B 878(9–10):743–748CrossRefGoogle Scholar
  29. 29.
    Rahman MM, Khan SB, Faisal M, Rub MA, Al-Youbi AO, Asiri AM (2012) Electrochemical determination of olmesartan medoxomil using hydrothermally prepared nanoparticles composed SnO2–Co3O4 nanocubes in tablet dosage forms. Talanta 99:924–931CrossRefGoogle Scholar
  30. 30.
    Shimooka K, Sawada Y, Tatematsu H (1989) Analysis of amlodipine in serum by a sensitive high-performance liquid chromatographic method with amperometric detection. J Pharm Biomed Anal 7(11):1267–1272CrossRefGoogle Scholar
  31. 31.
    Josefsson M, Zackrisson AL, Norlander B (1995) Sensitive high-performance liquid chromatographic analysis of amlodipine in human plasma with amperometric detection and a single-step solid-phase sample preparation. J Chromatogr B Biomed Sci Appl 672(2):310–313CrossRefGoogle Scholar
  32. 32.
    Jain PS, Patel MK, Gorle AP, Chaudhari AJ, Surana SJ (2012) Stability-indicating method for simultaneous estimation of olmesartan medoxomile, amlodipine besylate and hydrochlorothiazide by RP-HPLC in tablet dosage form. J Chromatogr Sci 50(8):680–687CrossRefGoogle Scholar
  33. 33.
    Rao JR, Rajput MP, Yadav SS, Mulla TS, Bharekar VV (2011) Simultaneous quantitation of olmesartan medoxomil, Amlodipine besylate and hydrochlorothiazide in pharmaceutical dosage form by using HPLC. Int J PharmTech Res 3(3):1435–1440Google Scholar
  34. 34.
    Kumar KK, Rao CK, Madhusudan G, Mukkanti K (2012) Rapid simultaneous determination of olmesartan—amlodipine and hydrochlorothiazide in combined pharmaceutical dosage form by stability-indicating ultra performance liquid chromatography. Am J Analyt Chem 3(01):50CrossRefGoogle Scholar
  35. 35.
    Kurbanoglu S, Gumustas M, Ozkan SA (2013) Simultaneous estimation and validation of some binary mixtures of antihypertensive drugs by RP-LC methods using two new generation silica columns. J Pharm Biomed Anal 72:198–201CrossRefGoogle Scholar
  36. 36.
    Hamrapurkar PD, Gadapayale KK (2013) Optimization and validation of RP-HPLC stability indicating method for determination of olmesartan medoxomil and its degraded product. Int J Appl Sci Eng 11(2):137–147Google Scholar
  37. 37.
    Zarghi A, Foroutan SM, Shafaati A, Khoddam A (2005) Validated HPLC method for determination of amlodipine in human plasma and its application to pharmacokinetic studies. Farmaco 60(9):789–792CrossRefGoogle Scholar
  38. 38.
    Jain PS, Patel MK, Gorle AP, Chaudhari AJ, Surana SJ (2012) Stability-indicating method for simultaneous estimation of olmesartan medoxomile, amlodipine besylate and hydrochlorothiazide by RP-HPLC in tablet dosage form. J Chromatogr Sci 50(8):680–687CrossRefGoogle Scholar
  39. 39.
    ICH guideline (Q2A) (R1) (2005) Validation of analytical procedures: text and methodology. Accessed 18 Jan 2019

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Pritesh R. Desai
    • 1
    Email author
  • Priti J. Mehta
    • 2
  • Avani B. Chokshi
    • 3
  1. 1.Department of Analytical ResearchZydus Cadila Healthcare LimitedAhmedabadIndia
  2. 2.Institute of PhamacyNirma UniversityAhmedabadIndia
  3. 3.Ramanbhai Patel College of PharmacyCHARUSATChangaIndia

Personalised recommendations